Methods and compositions for treating pulmonary hypertension
AssigneeAbraxis BioScience, LLC
InventorsNeil P. DESAI, Patrick SOON-SHIONG
Life of this patent
Estimating the term…
Abstract
The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof.
Claims21
A method of treating pulmonary hypertension in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein.
4-5. (canceled)
11-13. (canceled)
(canceled)
A unit dosage form for treatment of pulmonary hypertension comprising (a) nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof, wherein the amount of the rapamycin or derivative thereof in the unit dosage form is in the range of about 5 mg to about 500 mg, and (b) a pharmaceutically acceptable carrier.
20-60. (canceled)
A unit dosage form for treatment of pulmonary hypertension comprising (a) nanoparticles that comprise a carrier protein and a taxane or a derivative thereof, wherein the amount of the taxane or derivative thereof in the unit dosage form is in the range of about 5 mg to about 500 mg, and (b) a pharmaceutically acceptable carrier.
62-84. (canceled)
A method of treating pulmonary hypertension in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein and a composition comprising nanoparticles that comprise a taxane or a derivative thereof and a carrier protein.
86-101. (canceled)
Dependencies are inferred from the claim text.